- Home
- VIGL vs ORMP Comparison
VIGL vs ORMP Comparison
Compare VIGL & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ORMP
- Stock Information
- Founded
- VIGL 2020
- ORMP 2002
- Country
- VIGL United States
- ORMP United States
- Employees
- VIGL N/A
- ORMP N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- ORMP Health Care
- Exchange
- VIGL Nasdaq
- ORMP Nasdaq
- Market Cap
- VIGL 134.9M
- ORMP N/A
- IPO Year
- VIGL 2022
- ORMP N/A
- Fundamental
- Price
- VIGL $8.02
- ORMP $2.17
- Analyst Decision
- VIGL Buy
- ORMP Hold
- Analyst Count
- VIGL 7
- ORMP 1
- Target Price
- VIGL $8.00
- ORMP N/A
- AVG Volume (30 Days)
- VIGL 1.4M
- ORMP 61.6K
- Earning Date
- VIGL 08-12-2025
- ORMP 08-15-2025
- Dividend Yield
- VIGL N/A
- ORMP N/A
- EPS Growth
- VIGL N/A
- ORMP N/A
- EPS
- VIGL N/A
- ORMP N/A
- Revenue
- VIGL N/A
- ORMP $2,000,000.00
- Revenue This Year
- VIGL N/A
- ORMP N/A
- Revenue Next Year
- VIGL N/A
- ORMP N/A
- P/E Ratio
- VIGL N/A
- ORMP N/A
- Revenue Growth
- VIGL N/A
- ORMP 196.74
- 52 Week Low
- VIGL $1.31
- ORMP $1.82
- 52 Week High
- VIGL $8.03
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- VIGL 89.24
- ORMP 49.24
- Support Level
- VIGL $7.86
- ORMP $2.09
- Resistance Level
- VIGL $7.96
- ORMP $2.22
- Average True Range (ATR)
- VIGL 0.03
- ORMP 0.09
- MACD
- VIGL -0.16
- ORMP -0.00
- Stochastic Oscillator
- VIGL 83.33
- ORMP 55.26
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.